Advertisement

European Journal of Clinical Pharmacology

, Volume 10, Issue 6, pp 387–393 | Cite as

Comparison of the pharmacokinetics of intravenous dl-propranolol in borderline and permanent hypertension

  • Y. A. Weiss
  • M. E. Safar
  • C. Chevillard
  • A. Frydman
  • A. Simon
  • P. Lemaire
  • J. M. Alexandre
Originals

Summary

In borderline and permanent hypertensives after rapid i.v. injection of dl-propranolol 0.2 mg/kg plasma levels were measured and were fitted to a two-compartment open-model. In borderline patients, characterized by a high basal cardiac output (CO), plasma levels were always lower than in permanent hypertensives. The biological half-life was reduced and the central volume of distribution, volume of distribution at pseudo-equilibrium and total clearance (TC) were markedly increased. In the overall population, there was a significant positive correlation between CO and TC. Rapid achievement of a predetermined plateau in each group constituted experimental proof of the validity of the two-compartment open-model for kinetic analysis of propranolol i.v. If kinetic parameters from permanent hypertensives were applied to borderline hypertensives a lower plateau was obtained. Thus, in so far as β-blockade is related to plasma level of propranolol, an increased intravenous dose may be required in patients with high CO.

Key words

Pharmacokinetics dl-propranolol borderline hypertensives permanent hypertensives cardiac output 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bello, S.T., Sevy, R.W., Harakal, C.: Varying hemodynamic patterns in essential hypertension. Amer. J. med. Sci.250, 24–35 (1965)Google Scholar
  2. Branch, R.A., Shand, D.G., Nies, A.S.: Increase in hepatic blood flow and d-propranolol clearance by glucagon in the monkey. J. Pharmacol. exp. Ther.187, 581–587 (1973)Google Scholar
  3. Branch, R.A., Shand, D.G., Wilkinson, G.R., Nies, A.S.: Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. J. clin. Invest.53, 1101–1107 (1974)Google Scholar
  4. Eich, R.H., Peters, R.J., Cuddy, R.P.: The hemodynamics in labile hypertension. Amer. Heart J.63, 188–195 (1962)Google Scholar
  5. Evans, G.H., Nies, A.S., Shand, D.G.: The disposition of propranolol. III. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat. J. Pharmacol. exp. Ther.186, 114–122 (1973)Google Scholar
  6. Gibaldi, M., Nagashima, R., Levy, G.: Relationship between drug concentration in plasma or serum and amount of drug in the body. J. Pharm. Sci.58, 193–197 (1969)Google Scholar
  7. Julius, S., Pascual, A.V., London, R.: Role of parasympathetic inhibition in the hyperkinetic type of borderline hypertension. Circulation44, 413–417 (1971)Google Scholar
  8. Julius, S., Conway, J.: Hemodynamic studies with borderline blood pressure elevation. Circulation38, 282–288 (1968)Google Scholar
  9. Lowenthal, D.T., Briggs, W.A., Gibson, T.P., Nelson, H., Cirksena, W.J.: Pharmacokinetics of oral propranolol in chronic and renal disease. Clin. Pharmacol. Ther.16, 761–769 (1974)Google Scholar
  10. Lund-Johansen, P.: Hemodynamics in early essential hypertension. Acta med. scand.482, (Suppl.) 1–105 (1967)Google Scholar
  11. Mitenko, P.A., Ogilvie, R.I.: Rapidly achieved plasma concentration plateaus, with observations on theophylline kinetics. Clin. Pharmacol. Ther.13, 329–335 (1972)Google Scholar
  12. Nies, A.S., Evans, G.H., Shand, D.G.: Regional hemodynamic effects of beta-adrenergic blockade with propranolol in the unanesthetized primate. Amer. Heart. J.85, 97–102 (1973)Google Scholar
  13. Paterson, J.W., Conolly, M.E., Dollery, C.T.: The pharmacodynamics and metabolism of propranolol in man. Pharmacol. Clin.2, 127–133 (1970)Google Scholar
  14. Prichard, B.N.C., Gillam, P.M.S.: Treatment of hypertension with propranolol. Brit. med. J.1969 I, 7–16Google Scholar
  15. Safar, M., Milliez, P.: Hemodynamic findings in human arterial hypertension. Rev. Europ. Etud. Clin. Biol.17, 147–154 (1972)Google Scholar
  16. Safar, M., London, G., Weiss, Y., Milliez, P.: Vascular reactivity to norepinephrine and hemodynamic parameters in borderline hypertension. Amer. Heart J.89, 480–486 (1975)Google Scholar
  17. Shand, D.G., Evans, G.H., Nies, A.S.: The almost complete hepatic extraction of propranolol during intravenous administration in the dog. Life Sci.10, 1417–1421 (1971)Google Scholar
  18. Shand, D.G., Nuckolls, E.M., Oates, J.A.: Plasma propranolol level in adults with observations in four children. Clin. Pharmacol. Ther.11, 112–120 (1970)Google Scholar
  19. Shand, D.G., Rangno, R.E.: The disposition of propranolol. I. Elimination during oral absorption in man. Pharmacology (Basel)7, 159–168 (1972)Google Scholar
  20. Shand, D.G., Rangno, R.E., Evans, G.H.: The disposition of propranolol. II. Hepatic elimination in the rat. Pharmacology (Basel)8, 344–352 (1972)Google Scholar
  21. Stenson, R.E., Constantino, R.T., Harrison, D.C.: Interrelationships of hepatic blood flow, cardiac output and blood levels of lidocaine in man. Circulation43, 205–211 (1971)Google Scholar
  22. Wolfson, S., Gorlin, R.: Physiological and clinical aspects of beta-adrenergic blockade. Ann. N.Y. Acad. Sci.139, 1003–1009 (1967)Google Scholar
  23. Zacharias, R.J., Cowen, K.J., Prestt, J., Vickers, J., Wall, B.G.: Propranolol in hypertension: A study of long-term therapy 1964–1970. Amer. Heart J.83, 755–761 (1972)Google Scholar

Copyright information

© Springer-Verlag 1976

Authors and Affiliations

  • Y. A. Weiss
    • 1
  • M. E. Safar
    • 1
  • C. Chevillard
    • 1
  • A. Frydman
    • 1
  • A. Simon
    • 1
  • P. Lemaire
    • 1
  • J. M. Alexandre
    • 1
  1. 1.Pharmacology Laboratory and Hemodynamic Laboratory of the Hypertension Research CenterBroussais HospitalParisFrance

Personalised recommendations